GW501516 is an experimental drug that was never approved for human use. Originally developed by GlaxoSmithKline in 1992, it activates a specific receptor in cells that shifts the body’s fuel preference from carbohydrates to fat. You may have seen it sold online under the name “Cardarine” or “Endurobol,” often misleadingly marketed alongside SARMs (selective androgen receptor modulators), even though it belongs to an entirely different class of compounds. Development was abandoned after animal studies linked it to cancer, and it remains unapproved by the FDA.
How GW501516 Works in the Body
GW501516 activates something called the PPARδ receptor, a type of protein inside cells that acts like a switch for gene expression. When this receptor is turned on, it tells cells to ramp up fat burning and dial down their reliance on glucose. In animal studies, treated mice burned fatty acids as their primary fuel source, which reduced glucose consumption and lowered lactate buildup in muscles. The compound also increased production of ketone bodies, a byproduct of fat metabolism, suggesting deep shifts in how energy is produced at the cellular level.
The practical result, at least in mice, is improved endurance. Animals treated with GW501516 could run significantly longer than untreated controls. The mechanism behind this appears to be twofold: muscles get better at oxidizing fat, and they produce less of the metabolic waste products that contribute to fatigue. Treated mice had higher blood glucose after exercise (because their muscles weren’t burning through sugar) and lower blood lactate, which is one of the compounds associated with that burning feeling during intense effort.
At the molecular level, GW501516 turns on genes involved in building new mitochondria (the energy-producing structures inside cells) and reprogramming muscle fibers. It also upregulates a key enzyme that effectively blocks carbohydrate burning in muscle tissue, forcing cells to rely on fat instead. This is the same type of metabolic shift that endurance training produces over months, which is why the compound attracted so much attention in the first place.
Why It Was Originally Developed
GlaxoSmithKline initially pursued GW501516 as a potential treatment for obesity, type 2 diabetes, dyslipidemia (unhealthy cholesterol levels), and metabolic syndrome. Early human trials showed genuinely promising lipid results. In subjects with low HDL (“good”) cholesterol, the compound raised HDL by up to 16.9%, reduced LDL (“bad”) cholesterol by 7.3%, and cut triglycerides by 16.9%. It also reduced very-low-density lipoprotein particles by 19% and intermediate-density lipoprotein by a striking 52%, while increasing the number of HDL particles by 10%, particularly the larger, more protective type.
These were impressive numbers for a single compound, and they explain why researchers were initially excited. A drug that could simultaneously raise good cholesterol, lower bad cholesterol, and reduce triglycerides would have been enormously valuable for patients with metabolic disease.
Why Development Was Abandoned
GlaxoSmithKline pulled GW501516 from clinical trials after animal studies found it caused cancer. The compound promoted tumor growth in multiple organs in rats. Some sellers of GW501516 online try to dismiss these findings by arguing the animals received excessively high doses, but this does not change the fundamental finding: activating this pathway aggressively enough to produce metabolic benefits also appears to carry serious carcinogenic risk. No long-term human safety data exists because the trials were halted before that stage.
This is a critical point. GW501516 never completed the clinical trial process. It was not rejected at the final stage for being slightly less effective than hoped. It was pulled because of a safety signal serious enough to stop all further development. Without completed human trials, there is no established safe dose, no understanding of long-term effects in people, and no data on how it interacts with other substances.
Not Actually a SARM
GW501516 is routinely sold alongside SARMs on supplement and research chemical websites, but it is not one. SARMs interact with androgen receptors, the same receptors that testosterone binds to, and they influence muscle growth and bone density through hormonal pathways. GW501516 has nothing to do with androgen receptors. It is a PPARδ agonist, meaning it works through a completely separate system that governs fat metabolism, energy production, and gene expression related to endurance.
This distinction matters because the side effect profiles are entirely different. SARMs carry risks related to hormone suppression, liver toxicity, and cardiovascular stress. GW501516’s risks center on its potential to promote cancer. Lumping them together, as most online vendors do, obscures the specific dangers of each compound.
Current Legal and Regulatory Status
The World Anti-Doping Agency (WADA) bans GW501516 at all times, both in and out of competition. It is classified as a metabolic modulator on the Prohibited List, sitting alongside other PPARδ agonists and AMPK activators. Any athlete subject to drug testing who uses it risks a ban.
In the United States, the FDA considers GW501516 an unapproved new drug. It is not approved for any medical use and is not recognized as safe or effective. As recently as December 2025, the FDA issued a warning letter to a company selling “Cardarine GW501516” online, stating that introducing the product into interstate commerce violates federal law. The warning letter noted that the FDA has safety concerns about products marketed as SARMs (a category under which GW501516 is commonly sold), citing life-threatening reactions including liver toxicity and increased risk of heart attack and stroke. The agency warned that continued sales could lead to seizure of products and legal injunction.
Companies selling GW501516 typically label it “for research purposes only” to create legal cover, but the FDA has made clear that when product labeling, websites, and marketing materials indicate the substance is intended for human consumption, this disclaimer does not hold up.
What Sellers Claim vs. What the Evidence Shows
Online vendors and fitness influencers promote GW501516 as a fat burner and endurance enhancer that works without hormonal side effects. The animal data does support that it shifts metabolism toward fat oxidation and improves endurance in mice. The early human lipid data showed real improvements in cholesterol profiles. These are not fabricated benefits.
The problem is that the same mechanism that produces these metabolic effects also promoted tumor development in animal models, and nobody knows what happens in humans who take it for weeks or months. The compound was designed to alter gene expression on a fundamental level, changing which genes are active in muscle and fat tissue. That kind of deep biological reprogramming is not something where short-term tolerability tells you much about long-term safety. People selling GW501516 are offering a compound that a major pharmaceutical company, one with billions of dollars at stake, decided was too dangerous to continue testing.